J & J pays $158 million to settle Texas Medicaid fraud lawsuit

Share this article:
J & J pays $158 million to settle Texas Medicaid fraud lawsuit
J & J pays $158 million to settle Texas Medicaid fraud lawsuit

Johnson & Johnson has agreed to pay $158 million to settle a Medicaid fraud lawsuit.

The lawsuit accused J & J subsidiary Janssen Pharmaceuticals of giving state officials kickbacks in exchange for putting the antipsychotic Risperdal on an approved list for Medicaid recipients. The suit also claimed that Janssen marketed the drug as being a safe and cost-effective, despite the fact that it was linked to an increased risk of stroke and death in elderly dementia patients. Risperdal is only approved to treat adult schizophrenia.

Lawyers representing the state of Texas originally asked that Janssen repay $579 million to the state's Medicaid program, plus up to $500 million in penalties, the Associated Press reported.

"Janssen ran amok,” Allen Jones, one of the plaintiffs, told the AP. “They trashed the Johnson & Johnson credo, and they misused Texas and, I believe, well-meaning officials to further their marketing.”

Johnson & Johnson was recently ordered to pay $327 million in South Carolina and the $258 million in Louisiana in similar Risperdal lawsuits.

Share this article:

More in News

CMS expands therapy payment research

The government is expanding its research into alternative therapy payments, to consider more holistic changes to the way Medicare reimburses skilled nursing facilities, the Centers for Medicare & Medicaid Services announced Tuesday.

CDC tightens Ebola guidelines for healthcare workers

The Centers for Disease Control and Prevention has issued more stringent guidelines for how healthcare workers should interact with Ebola patients, following an outcry from nurses and other professionals.

Nonprofit providers face alarming market forces, must rally, LeadingAge chairman says

Nonprofit providers face alarming market forces, must rally, ...

Nonprofit long-term care providers must work together to address alarming trends, or their market share could plummet and the sector as a whole could falter, LeadingAge Chairman David Gehm told ...